Melbourne-based specialty pharmaceutical company, Hatchtech, which is developing a next generation head lice treatment, today announced the successful completion of a A$12.6 million capital raise. The ...

Indian Drug maker, Dr Reddy's Laboratories has signed a commercialization deal with Australia's Hatchtech for its head lice product called the Xeglyze Lotion. As part of the agreement, Dr Reddy's will ...

Hatchtech announced separately said it would file a New Drug Application for Xeglyze with the U.S. FDA. Release (PDF) > Japan's Takeda Pharmaceutical joined the Search consortium that seeks to make ...

HYDERABAD, India--(BUSINESS WIRE)--Dr. Reddy’s Laboratories (NYSE: RDY) today announced the signing of a commercialization deal with Hatchtech, an Australian pharmaceutical company developing an ...

Hatchtech, a private Australian company, has been developing its treatment for more than 10 years. It originally targeted its product for sheep blowfly before original investor Uniseed suggested it ...

Australian pharmaceutical company Hatchtech has inked a deal worth up to $279 million with Indian giant Dr. Reddy's for the commercialisation of its innovative head ...

Add articles to your saved list and come back to them anytime. Biotechnology company Hatchtech says its new head lice treatment product will progress to phase two trials after it received the green ...

MELBOURNE, Australia--(BUSINESS WIRE)--Specialty pharmaceutical company Hatchtech Pty Ltd today announced positive results from its two pivotal Phase 3 clinical studies evaluating Xeglyze™ Lotion ...

Hatchtech Pty. Ltd., a specialty pharmaceutical company developing a treatment for head lice infestations, said it has completed a financing round with 7.8 million Australian dollars ($8.1 million) as ...

NEW DELHI: Drugmaker Dr Reddy's Laboratories said it has signed a commercialisation deal with Australia's Hatchtech for the latter's prescription head lice product Xeglyze Lotion. As part of the ...